1066:(an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease. The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks. Infliximab was studied in monotherapy (without concomitant immunosuppressants such as methotrexate or
522:
1058:(some fatal) have been reported with infliximab. The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully. The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents.
42:
915:
1273:'s (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU). Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013. Inflectra was approved for use in the European Union in September 2013, and Remsima was approved for use in the European Union in October 2013.
3799:
6722:
795:
evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.
3565:
3027:
1658:
1318:
Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder, so must be reconstituted and administered by a health care professional, usually in a hospital or office setting. For this reason, it is usually covered under major medical insurance rather than prescription drug coverage.
749:
in 56–68% of patients. A large, 296-patient Phase III clinical trial called the ACCENT 2 trial showed infliximab was additionally beneficial in maintaining closure of fistulae, with almost two-thirds of all patients treated with the three initial doses of infliximab having a fistula response after 14
3044:
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. (4 December 1999). "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study
762:
Infliximab has been used to induce and maintain remission in inflammatory Crohn's disease. The ACCENT 1 trial, a large, multicentre trial, found 39–45% of patients treated with infliximab, who had an initial response to it, maintained remission after 30 weeks, compared with 21% who received placebo
794:
disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul
Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to
819:
have the potential to reduce the signs and symptoms of moderate to severely active axial involvement in PsA in patients who have had an inadequate response to NSAID (level 1a, grade A). The anti-TNF agents (infliximab and etanercept; level 1b, grade A) are more effective for the treatment of
1654:
807:(PsA), inhibitors of TNF, such as infliximab, improve the signs and symptoms. Several therapies with modest efficacy have been studied in nail psoriasis. Among available agents, higher quality data are available to support the efficacy of
1144:-bound) of TNF-α. Etanercept, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNF-α. Additionally, the anti-TNF antibodies
1575:
1061:
Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with
3448:
2450:
Kavanaugh AF, Ritchlin CT, et al. (GRAPPA Treatment
Guideline Committee) (July 2006). "Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines".
1749:
688:
Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are
741:
Infliximab was first used for closure of fistulae in Crohn's disease in 1999. In a 94-patient, phase II clinical trial, the researchers showed infliximab was effective in closing fistulae between the
770:
medications to obtain remission, but steroids have many undesirable side effects, so some gastroenterologists are now advocating the use of infliximab as the first drug to try to get patients into
276:
693:
and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody".
2803:
Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. (May 2007). "The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease".
1337:
In
Australia, infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and has a severe case of the condition.
1330:
score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate. Since
February 2015, it is also approved for the treatment of
1136:(another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular-,
5667:
3590:
6787:
3004:
1655:"Celltrion USA Announces U.S. FDA Approval of Zymfentra (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease"
3646:
3614:
231:
3345:
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. (November 1993). "Construction and initial characterization of a mouse-human chimeric anti-TNF antibody".
2329:
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. (May 2002). "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial".
596:
1565:
3426:
2840:"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline"
3550:
3717:
6752:
1340:
Johnson & Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the
Company's total revenues for fiscal 2013."
861:
There have been numerous case reports of the efficacy of infliximab in various inflammatory skin conditions diseases; the FDA approved infliximab for chronic severe
1739:
3458:
1597:
1295:
released another biosimilar, Flixabi, which was approved in
Germany, the UK, and the Netherlands. Flixabi was approved for use in the European Union in May 2016.
3772:
3516:
125:
4225:
1500:
1459:
1420:
1379:
6777:
5660:
6767:
3737:
3296:
2954:
56:
3473:
3385:
5141:
1779:
763:
treatment. It also showed a mean maintenance of remission from 38 to 54 weeks compared with 21 weeks for patients who received placebo treatment.
5653:
1203:
3713:"Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy"
2976:
6676:
4188:
4174:
4154:
3831:
2096:
876:
701:
3582:
3484:
120:
infliximab-abda, infliximab-axxq, infliximab-dyyb, infliximab-qbtx, Avsola, Flixabi, Inflectra, Ixifi, Remsima, Renflexis, Zessly, Zymfentra
1279:
In India, Epirus
Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015).
883:
3012:
1276:
In Japan, Celltrion received marketing authorization for
Remsima from Japan's Ministry of Health, Labour and Welfare (MHLW) in July 2014.
858:. Half of the patients saw benefit from this treatment, and a few other patients experienced infections that in some cases lead to death.
2021:
3144:
2413:
2289:
2233:
1945:
3636:
3604:
1983:
1538:
3854:
2057:
1132:
and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. Infliximab and
5084:
4454:
3416:
954:
1327:
2887:
2258:
4218:
3538:
1905:
1879:
1853:
1827:
1801:
5493:
261:
157:
6772:
6762:
6648:
1688:
936:
2181:
Dubinsky MC, Fleshner PP (June 2003). "Treatment of Crohn's
Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes".
766:
Crohn's patients have flares of their disease between periods of disease quiescence. Severe flares are usually treated with
696:
Infliximab was approved for medical use in the United States in 1998, and in the
European Union in August 1999. Infliximab
3421:
2118:
Mouser JF, Hyams JS (June 1999). "Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease".
1005:
6712:
6742:
6658:
4290:
3544:
3008:
2983:
1494:
1453:
1414:
1373:
1283:
897:
resistant to initial IVIG therapy, showing better outcomes in fever resolution and fewer severe adverse effects such as
441:
3698:
2668:
6747:
6693:
4399:
4211:
4137:
3768:
3691:"The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease - Guidance and guidelines - NICE"
932:
501:
224:
176:
3676:
3508:
4269:
3723:
1192:
3199:"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity"
1152:
cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability.
925:
6242:
4947:
3824:
3453:
2690:
Kemta Lekpa F, Kraus VB, Chevalier X (April 2012). "Biologics in relapsing polychondritis: a literature review".
2153:
2051:
2015:
1977:
1939:
1532:
1488:
1447:
1408:
1367:
1270:
700:
have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019). It is on the
6757:
5327:
1232:
855:
3005:"Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009"
2962:
6782:
6681:
5322:
4181:
3864:
3745:
3478:
1125:
678:
660:
213:
5127:
4553:
4234:
3920:
3393:
1079:
1023:
890:
837:
783:
637:
490:
92:
3803:
1711:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
1171:
also binds and inhibits the action of TNF-α, but is not a monoclonal antibody (it is instead a fusion of
848:
649:
5754:
5676:
5314:
4077:
3971:
3925:
1771:
1141:
750:
weeks, and 36% of patients maintaining closure of fistulae after a year, compared with 19% who received
3246:
Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. (December 1991).
5958:
4203:
3817:
3389:
3142:
Choy EH, Panayi GS (March 2001). "Cytokine pathways and joint inflammation in rheumatoid arthritis".
1710:
1326:
treatment provided three criteria are met. Patients should have severe active Crohn's disease with a
1188:
1114:
841:
771:
633:
367:
2838:
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. (June 2018).
4535:
3899:
2987:
2481:
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. (April 2015).
1319:
The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages.
1098:
1075:
804:
690:
667:
653:
645:
621:
517:
385:
359:
66:
49:
3884:
3248:"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis"
2283:
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. (February 2004).
2088:
1236:
6143:
6102:
5942:
5734:
5484:
4585:
4102:
4026:
3327:
3070:
2913:
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. (2001).
2750:
2725:
Gupta AK, Skinner AR (2004). "A review of the use of infliximab to manage cutaneous dermatoses".
2660:
2354:
2224:
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. (May 1999).
2206:
1331:
1164:
1128:
to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of
1015:
971:
754:
therapy. This final trial resulted in the FDA approval of the drug to treat fistulizing disease.
629:
187:
5524:
5382:
1625:
1323:
722:
625:
5534:
5220:
4661:
2888:"Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians"
2631:
Puéchal X, Terrier B, Mouthon L, Costedoat-Chalumeau N, Guillevin L, Le Jeunne C (March 2014).
725:: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes
6034:
5704:
5645:
5489:
5479:
4280:
4238:
4161:
3869:
3362:
3319:
3277:
3228:
3161:
3124:
3062:
2936:
2869:
2820:
2785:
2742:
2707:
2652:
2610:
2561:
2512:
2460:
2432:
2389:
2346:
2308:
2250:
2198:
2135:
2010:
1091:
670:
301:
288:
105:
71:
1934:
6024:
6014:
5285:
5188:
4851:
4747:
3915:
3874:
3449:"European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars"
3354:
3311:
3267:
3259:
3218:
3210:
3153:
3114:
3104:
3054:
2926:
2859:
2851:
2812:
2777:
2734:
2699:
2644:
2600:
2592:
2551:
2543:
2502:
2494:
2422:
2381:
2338:
2298:
2242:
2190:
2161:
2127:
1972:
1527:
1095:
1051:
1009:
898:
894:
862:
664:
538:
394:
336:
3091:
Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, et al. (November 2015).
2530:
Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. (22 July 2002).
2046:
450:
6726:
6442:
6218:
5584:
5469:
4062:
3951:
3930:
3386:"Remicade Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide"
1240:
1224:
354:
344:
2407:
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. (2005).
2507:
2482:
1289:
The FDA approved Samsung Bioepis Co., Ltd.'s Renflexis (infliximab-abda) in April 2017.
729:
or abnormal connections of the bowel), and inflammatory disease (which primarily causes
521:
6687:
5474:
5342:
4990:
4824:
4803:
4799:
4795:
4423:
4260:
4117:
3859:
3840:
3263:
3223:
3198:
3119:
3092:
2915:"Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent"
2864:
2839:
2605:
2580:
2556:
2531:
2225:
1265:
versions (Inflectra and Remsima) were submitted for approval in the European Union, by
967:
Infliximab has adverse effects, some life-threatening, common to drugs in the class of
3272:
3247:
3058:
2342:
2131:
824:
than traditional agents. Results suggest infliximab is effective for the treatment of
41:
6736:
6597:
6398:
6343:
6268:
6228:
6148:
6042:
5688:
5680:
5624:
5554:
5464:
5371:
5157:
4857:
4779:
4731:
4711:
4569:
4485:
4336:
4302:
4067:
3981:
3894:
3641:
3609:
3569:
3358:
3031:
2703:
2664:
1744:
1602:
1570:
1286:(FDA) approved Celltrion/Hospira/Pfizer's Inflectra (infliximab-dyyb) in April 2016.
1244:
1199:
1137:
1020:
968:
791:
787:
314:
149:
2754:
2210:
6587:
6572:
6552:
6542:
6521:
6437:
6378:
6363:
6333:
6313:
6308:
6283:
6263:
6258:
6253:
6203:
6193:
6183:
6133:
6128:
6123:
6052:
5937:
5921:
5824:
5814:
5809:
5784:
5724:
5634:
5594:
5579:
5574:
5290:
5240:
5235:
5215:
5095:
5090:
4953:
4938:
4886:
4862:
4809:
4686:
4676:
4495:
4412:
4407:
4365:
4318:
4275:
4242:
4107:
4006:
3889:
3879:
3331:
3093:"Promising biological therapies for ulcerative colitis: A review of the literature"
2498:
2358:
1067:
1063:
1055:
999:
808:
730:
244:
239:
3074:
1680:
135:
2648:
889:
Infliximab has been found to be a safe alternative treatment to a second dose of
6653:
6643:
6582:
6567:
6557:
6547:
6526:
6511:
6496:
6491:
6486:
6461:
6414:
6393:
6388:
6383:
6373:
6368:
6353:
6328:
6318:
6298:
6278:
6273:
6238:
6233:
6223:
6213:
6208:
6178:
6168:
6138:
6092:
6087:
6077:
6062:
6047:
6019:
6004:
5989:
5984:
5979:
5947:
5890:
5885:
5875:
5855:
5834:
5829:
5799:
5719:
5629:
5569:
5559:
5549:
5449:
5439:
5429:
5424:
5389:
5300:
5295:
5270:
5260:
5250:
5225:
5210:
5205:
5163:
5133:
5119:
5114:
5100:
5043:
5001:
4996:
4982:
4977:
4963:
4943:
4896:
4872:
4830:
4814:
4785:
4769:
4737:
4721:
4716:
4691:
4641:
4631:
4626:
4621:
4610:
4600:
4505:
4417:
4375:
4360:
4354:
4350:
4297:
4167:
4082:
4036:
4031:
4016:
4011:
4001:
3976:
3157:
2596:
2246:
1256:
1047:
993:
914:
869:
220:
143:
3669:"Remicade (Infliximab): Side Effects, Interactions, Warning, Dosage & Uses"
6613:
6592:
6577:
6562:
6506:
6501:
6481:
6476:
6447:
6421:
6358:
6338:
6323:
6303:
6293:
6248:
6198:
6188:
6163:
6158:
6153:
6118:
6113:
6082:
6009:
5999:
5994:
5974:
5911:
5906:
5895:
5865:
5860:
5804:
5779:
5764:
5749:
5744:
5714:
5619:
5614:
5599:
5539:
5529:
5514:
5509:
5504:
5454:
5444:
5434:
5399:
5377:
5363:
5275:
5265:
5255:
5245:
5230:
5173:
5168:
5147:
5062:
5057:
5015:
5009:
4910:
4867:
4763:
4753:
4706:
4696:
4671:
4666:
4656:
4651:
4646:
4636:
4580:
4575:
4559:
4500:
4480:
4429:
4389:
4370:
4312:
4097:
4092:
4046:
4041:
3996:
3956:
3935:
2816:
2781:
2738:
2547:
2194:
1304:
In December 2019, Avsola (infliximab-axxq) was approved in the United States.
1262:
1168:
1160:
1145:
1133:
1043:
825:
821:
816:
812:
767:
697:
577:
425:
115:
2855:
2158:
World Health Organization model list of essential medicines: 22nd list (2021)
1343:
Zymfentra was approved for medical use in the United States in October 2023.
1298:
In December 2017, Ixifi (infliximab-qbtx) was approved in the United States.
6516:
6348:
6173:
6072:
6057:
5916:
5880:
5870:
5844:
5839:
5819:
5794:
5789:
5774:
5769:
5739:
5709:
5609:
5604:
5589:
5564:
5519:
5499:
5459:
5394:
5358:
5280:
5076:
5029:
4958:
4924:
4891:
4701:
4681:
4590:
4490:
4330:
4072:
4021:
3986:
3966:
3961:
3809:
3690:
2372:
Hanauer SB (February 2003). "Crohn's disease: step up or top down therapy".
1176:
1156:
1121:
1071:
1029:
987:
718:
674:
641:
129:
3323:
3214:
3165:
3128:
3109:
3066:
2940:
2873:
2824:
2789:
2746:
2711:
2656:
2632:
2614:
2565:
2516:
2464:
2436:
2393:
2385:
2350:
2312:
2254:
2226:"Infliximab for the treatment of fistulas in patients with Crohn's disease"
2202:
2139:
1117:
of 9.5 days and can be detected in serum 8 weeks after infusion treatment.
33:
3798:
3668:
3366:
3281:
3232:
2581:"Behçet's disease: a new target for anti-tumour necrosis factor treatment"
1195:
and colleagues in proof of principle studies in transgenic animal models.
879:(COPD) but there was no evidence of benefit with the possibility of harm.
5926:
5849:
5759:
5729:
5544:
5419:
5108:
4616:
4526:
4462:
4384:
4112:
3991:
3474:"European Commission Approves Biosimilar of J&J and Merck's Remicade"
2931:
2914:
2427:
2409:"Infliximab for induction and maintenance therapy for ulcerative colitis"
2408:
2303:
2284:
1854:"Inflectra- infliximab-dyyb injection, powder, lyophilized, for solution"
1228:
1207:
1110:
1106:
1102:
1036:
682:
405:
171:
3712:
2166:
1269:
and Celltrion Healthcare respectively. Both had a positive opinion from
811:
and infliximab. Based on studies in AS, the results suggest infliximab,
414:
17:
6403:
6288:
5037:
3583:"Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars"
1266:
1129:
939: in this section. Unsourced material may be challenged and removed.
847:
Infliximab is also prescribed (out of indication) for the treatment of
751:
726:
87:
2768:
Wijsenbeek MS, Culver DA (December 2015). "Treatment of Sarcoidosis".
1828:"Avsola- infliximab-axxq injection, powder, lyophilized, for solution"
1740:"Health product highlights 2021: Annexes of products approved in 2021"
6628:
5352:
5183:
1292:
1149:
1113:
combined with human heavy and light chain constant regions. It has a
979:
975:
481:
3315:
1880:"Renflexis- infliximab injection, powder, lyophilized, for solution"
854:
Infliximab is the most frequently used biological agent in treating
1802:"Remicade- infliximab injection, powder, lyophilized, for solution"
470:
5051:
4904:
3417:"Billion-dollar biotech drug may soon have biosimilar competition"
3297:"Regulation of tumour necrosis factor signalling: live or let die"
1172:
746:
79:
75:
3568:
This article incorporates text from this source, which is in the
3030:
This article incorporates text from this source, which is in the
5023:
4971:
4932:
4918:
4472:
4346:
2285:"Infliximab maintenance therapy for fistulizing Crohn's disease"
1310:
In December 2021, Ixifi was approved for medical use in Canada.
742:
461:
323:
295:
5649:
4207:
3813:
1301:
Zessly was approved for use in the European Union in May 2018.
308:
166:
4880:
1718:
908:
1307:
Avsola was approved for medical use in Canada in March 2020.
616:, a chimeric monoclonal antibody, sold under the brand name
506:
2626:
2624:
774:. This has been called the top-down approach to treatment.
270:
198:
868:
Infliximab has been used off-label in treating refractory
2089:"Infliximab, Infliximab-dyyb Monograph for Professionals"
3509:"Epirus racks up its first biosimilar approval in India"
1566:"Health Canada New Drug Authorizations: 2016 Highlights"
1442:
1440:
1438:
1362:
1360:
1358:
1356:
620:
among others, is a medication used to treat a number of
283:
702:
World Health Organization's List of Essential Medicines
603:
3380:
3378:
3376:
3187:
Etanercept, Adalimumab and Infliximab product labeling
2532:"Infliximab for the treatment of rheumatoid arthritis"
6710:
1403:
1401:
1399:
1397:
1198:
Infliximab was developed by Junming Le (b. 1940) and
1560:
1558:
1556:
1483:
1481:
1479:
1477:
1368:"Drug Approval Package: Renflexis (infliximab-abda)"
1322:
In the UK, infliximab is available from the NHS for
6636:
6626:
6606:
6535:
6469:
6460:
6429:
6101:
6033:
5967:
5696:
5687:
5412:
5340:
5313:
5198:
4841:
4543:
4534:
4525:
4518:
4471:
4453:
4444:
4398:
4329:
4259:
4250:
4146:
4130:
4055:
3944:
3908:
3847:
576:
537:
532:
500:
480:
460:
440:
424:
404:
384:
379:
366:
353:
343:
335:
260:
255:
230:
212:
186:
156:
142:
124:
114:
104:
99:
86:
65:
55:
48:
3539:"FDA approves Inflectra, a biosimilar to Remicade"
3483:
1120:Infliximab neutralizes the biological activity of
1090:Infliximab is a purified, recombinant DNA-derived
872:, where other treatments have not been effective.
790:cytokines. Ulcerative colitis was thought to be a
673:. It seems to work by binding to and neutralizing
3718:National Institute for Health and Care Excellence
3097:World Journal of Gastrointestinal Pathophysiology
2483:"TNF-alpha inhibitors for ankylosing spondylitis"
2095:. American Society of Health-System Pharmacists.
2005:
2003:
2001:
1929:
1927:
1489:"Drug Approval Package: Ixifi (infliximab-qbtx)"
1155:Other monoclonal antibodies targeting TNF-α are
3738:"Section 100 arrangements; only for infliximab"
1967:
1965:
1963:
882:Infliximab is indicated for steroid refractory
393:
27:Biopharmaceutical drug for autoimmune disorders
2041:
2039:
1649:
1647:
1522:
1520:
1518:
6788:World Health Organization essential medicines
5661:
4219:
3825:
3766:JNJ annual report, downloaded 22 April 2014.
685:) and a key part of the autoimmune reaction.
656:, typically at six- to eight-week intervals.
8:
3605:"Summary Basis of Decision (SBD) for Avsola"
1772:"Regulatory Decision Summary for Remsima SC"
1187:The importance of TNF in the development of
681:on the cell. TNF-α is a chemical messenger (
175:
32:
3637:"Summary Basis of Decision (SBD) for Ixifi"
2536:The Cochrane Database of Systematic Reviews
2487:The Cochrane Database of Systematic Reviews
2083:
2081:
2079:
2077:
2075:
1626:"Regulatory Decision Summary for Renflexis"
1448:"Inflectra (infliximab-dyyb) for Injection"
721:, or categories of disease, are present in
6633:
6466:
5693:
5668:
5654:
5646:
4540:
4531:
4522:
4450:
4256:
4226:
4212:
4204:
4052:
3832:
3818:
3810:
2476:
2474:
2324:
2322:
677:, preventing it from interacting with its
520:
40:
3271:
3222:
3118:
3108:
3086:
3084:
2930:
2863:
2604:
2555:
2506:
2426:
2302:
2165:
955:Learn how and when to remove this message
449:
6753:Drugs developed by Johnson & Johnson
3295:Brenner D, Blaser H, Mak TW (May 2015).
3197:Peppel K, Crawford D, Beutler B (1991).
2977:"Remicade (infliximab) for IV Injection"
1334:where other treatments have not worked.
659:Common side effects include infections,
6717:
2955:"Remicade for Healthcare Professionals"
1352:
516:
413:
148:
3679:from the original on 18 December 2009.
1906:"Zymfentra- infliximab-dyyb injection"
1204:New York University School of Medicine
1148:and infliximab have the capability of
663:, and abdominal pain. Infliximab is a
31:
4155:Merck Manual of Diagnosis and Therapy
3593:from the original on 28 October 2016.
3011:(FDA). 31 August 2009. Archived from
2264:from the original on 18 February 2019
2160:. Geneva: World Health Organization.
2060:from the original on 30 December 2019
1986:from the original on 29 December 2019
1691:from the original on 30 November 2020
1661:from the original on 25 December 2023
1503:from the original on 18 December 2019
1382:from the original on 18 December 2019
1231:Biotech, Inc.) in the United States,
877:chronic obstructive pulmonary disease
489:
134:
7:
3553:from the original on 7 December 2019
3519:from the original on 29 October 2014
2692:Seminars in Arthritis and Rheumatism
2671:from the original on 5 November 2018
2024:from the original on 16 October 2019
1948:from the original on 22 October 2020
1541:from the original on 16 October 2019
1423:from the original on 1 November 2020
937:adding citations to reliable sources
884:checkpoint inhibitor induced colitis
243:
3701:from the original on 30 April 2010.
3145:The New England Journal of Medicine
2414:The New England Journal of Medicine
2290:The New England Journal of Medicine
2234:The New England Journal of Medicine
1008:(generally only when combined with
886:, at a dose of 5 to 10 mg/kg.
469:
349:92% (IV, if 8% left in the syringe)
6778:Drugs developed by Schering-Plough
6768:Drugs developed by Merck & Co.
3726:from the original on 6 March 2015.
3549:(Press release). 6 December 2019.
3264:10.1002/j.1460-2075.1991.tb04978.x
1752:from the original on 25 March 2024
840:, psoriatic arthritis, psoriasis,
25:
3775:from the original on 5 March 2016
3392:. 6 November 2007. Archived from
2374:Best Pract Res Clin Gastroenterol
2099:from the original on 15 July 2019
1782:from the original on 2 April 2024
1681:"Infliximab Use During Pregnancy"
1578:from the original on 7 April 2024
982:)). Some of the most severe are:
974:(which also includes etanercept (
6720:
3797:
3649:from the original on 29 May 2022
3617:from the original on 30 May 2022
3563:
3472:Rockoff JD (10 September 2013).
3429:from the original on 1 July 2013
3025:
2704:10.1016/j.semarthrit.2011.08.006
2183:Curr Treat Options Gastroenterol
1462:from the original on 20 May 2022
913:
786:, thought to be more related to
555:
549:
2986:(FDA). May 2006. Archived from
1776:Drug and Health Products Portal
1630:Drug and Health Products Portal
1409:"Drug Approval Package: Avsola"
1191:was originally demonstrated by
924:needs additional citations for
3457:. 28 June 2013. Archived from
2499:10.1002/14651858.CD005468.pub2
1657:. Celltrion. 22 October 2023.
875:Infliximab has been tested in
567:
561:
543:
1:
3422:Philadelphia Business Journal
3059:10.1016/s0140-6736(99)05246-0
2805:Am. J. Respir. Crit. Care Med
2579:Sfikakis PP (November 2002).
2343:10.1016/S0140-6736(02)08512-4
2132:10.1016/s0149-2918(99)80015-0
2126:(6): 932–42, discussion 931.
1210:(now Janssen Biotech, Inc.).
1032:and psoriasiform skin lesions
1006:hepatosplenic T-cell lymphoma
865:in adults in September 2006.
836:It was approved for treating
4291:dihydroorotate dehydrogenase
3545:Food and Drug Administration
3359:10.1016/0161-5890(93)90106-L
3009:Food and Drug Administration
2984:Food and Drug Administration
2844:Journal of Clinical Oncology
2649:10.1016/j.jbspin.2014.01.001
1495:Food and Drug Administration
1454:Food and Drug Administration
1415:Food and Drug Administration
1374:Food and Drug Administration
1284:Food and Drug Administration
4270:purine synthesis inhibitors
4138:Merck Headquarters Building
3178:Etanercept product labeling
3158:10.1056/NEJM200103223441207
2597:10.1136/ard.61.suppl_2.ii51
2247:10.1056/NEJM199905063401804
6804:
2633:"Relapsing polychondritis"
2170:. WHO/MHP/HPS/EML/2021.02.
1669:– via Business Wire.
1314:Availability/affordability
1254:
1206:and in collaboration with
654:slow injection into a vein
533:Chemical and physical data
6671:
4455:IL-1 receptor antagonists
3454:European Medicines Agency
3415:George J (28 June 2013).
2817:10.1164/rccm.200607-995OC
2782:10.1016/j.ccm.2015.08.015
2770:Clinics in Chest Medicine
2739:10.1007/s10227-004-0115-7
2548:10.1002/14651858.cd003785
2195:10.1007/s11938-003-0001-1
2154:World Health Organization
2052:European Medicines Agency
2016:European Medicines Agency
1978:European Medicines Agency
1940:European Medicines Agency
1533:European Medicines Agency
1271:European Medicines Agency
593:
39:
5328:Anti-lymphocyte globulin
3742:medicareaustralia.gov.au
2856:10.1200/JCO.2017.77.6385
1233:Mitsubishi Tanabe Pharma
1223:Remicade is marketed by
1177:antibody constant region
856:relapsing polychondritis
661:acute infusion reactions
5323:Anti-thymocyte globulin
4235:Immunosuppressive drugs
3479:The Wall Street Journal
1101:that consists of mouse
712:
291: / Schedule D
5128:Interleukin-6 receptor
4554:Complement component 5
3921:Cubist Pharmaceuticals
3215:10.1084/jem.174.6.1483
3110:10.4291/wjgp.v6.i4.219
2386:10.1053/bega.2003.0361
1080:ankylosing spondylitis
1024:central nervous system
838:ankylosing spondylitis
638:ankylosing spondylitis
93:Tumor necrosis factors
6773:Monoclonal antibodies
6763:Janssen Pharmaceutica
5755:Camidanlumab tesirine
5677:Monoclonal antibodies
4078:Ezetimibe/simvastatin
3972:Ezetimibe/simvastatin
3926:H. K. Mulford Company
3841:Merck & Co., Inc.
3390:Johnson & Johnson
2120:Clinical Therapeutics
1124:by binding with high
691:monoclonal antibodies
6430:Chimeric + humanized
5959:Nivolumab/relatlimab
3806:at Wikimedia Commons
3722:. 25 February 2015.
3695:guidance.nice.org.uk
3461:on 17 February 2015.
2932:10.1056/NEJMoa011110
2428:10.1056/NEJMoa050516
2304:10.1056/NEJMoa030815
1778:. 15 February 2024.
1499:. 29 November 2018.
1378:. 10 December 2018.
1189:rheumatoid arthritis
933:improve this article
842:rheumatoid arthritis
758:Inflammatory disease
634:rheumatoid arthritis
6743:Engineered proteins
3848:Corporate directors
3748:on 3 September 2011
3645:. 23 October 2014.
3613:. 23 October 2014.
3589:. 27 October 2016.
3015:on 15 November 2009
2591:(Suppl 2): ii51–3.
1419:. 30 January 2020.
1214:Society and culture
1099:monoclonal antibody
1076:psoriatic arthritis
805:psoriatic arthritis
799:Psoriatic arthritis
782:Infliximab targets
737:Fistulizing disease
668:monoclonal antibody
646:psoriatic arthritis
622:autoimmune diseases
360:reticuloendothelial
304:(Prescription only)
279:(Prescription only)
50:Monoclonal antibody
36:
6748:Immunosuppressants
6698:Never to phase III
6144:Certolizumab pegol
6111:Immunosuppressive:
5485:Diroximel fumarate
5158:IL-2 receptor/CD25
4586:Certolizumab pegol
4239:Immunosuppressants
4103:Rocuronium bromide
4027:rVSV-ZEBOV vaccine
3488:on 25 January 2017
2993:on 9 October 2006.
1332:ulcerative colitis
1261:In June 2013, two
1165:certolizumab pegol
1016:drug-induced lupus
978:) and adalimumab (
972:immunosuppressants
778:Ulcerative colitis
630:ulcerative colitis
6708:
6707:
6667:
6666:
6622:
6621:
6456:
6455:
6411:Immune activation
5903:Immune activation
5705:Immunosuppression
5643:
5642:
5490:Efgartigimod alfa
5480:Dimethyl fumarate
5408:
5407:
5336:
5335:
5309:
5308:
4514:
4513:
4440:
4439:
4281:Mycophenolic acid
4201:
4200:
4162:The Merck Manuals
4126:
4125:
3802:Media related to
3697:. 26 April 2002.
3388:(Press release).
2925:(15): 1098–1104.
2850:(17): 1714–1768.
1886:. 26 January 2023
1748:. 3 August 2022.
1632:. 1 December 2017
1574:. 14 March 2017.
1227:, Inc. (formerly
965:
964:
957:
652:. It is given by
611:
610:
502:CompTox Dashboard
327:
312:
299:
286:
274:
202:
169:
16:(Redirected from
6795:
6725:
6724:
6723:
6716:
6634:
6467:
6025:Zolimomab aritox
6015:Telimomab aritox
5694:
5670:
5663:
5656:
5647:
5286:Telimomab aritox
5189:Zolimomab aritox
5010:CD62L/L-selectin
4748:Immunoglobulin E
4541:
4532:
4523:
4451:
4257:
4228:
4221:
4214:
4205:
4053:
3916:Acceleron Pharma
3875:Rochelle Lazarus
3865:William Harrison
3834:
3827:
3820:
3811:
3801:
3785:
3784:
3782:
3780:
3769:"2013 1229 10-K"
3764:
3758:
3757:
3755:
3753:
3744:. Archived from
3734:
3728:
3727:
3709:
3703:
3702:
3687:
3681:
3680:
3665:
3659:
3658:
3656:
3654:
3633:
3627:
3626:
3624:
3622:
3601:
3595:
3594:
3579:
3573:
3567:
3566:
3562:
3560:
3558:
3535:
3529:
3528:
3526:
3524:
3504:
3498:
3497:
3495:
3493:
3487:
3482:. Archived from
3469:
3463:
3462:
3445:
3439:
3438:
3436:
3434:
3412:
3406:
3405:
3403:
3401:
3382:
3371:
3370:
3342:
3336:
3335:
3301:
3292:
3286:
3285:
3275:
3252:The EMBO Journal
3243:
3237:
3236:
3226:
3194:
3188:
3185:
3179:
3176:
3170:
3169:
3139:
3133:
3132:
3122:
3112:
3088:
3079:
3078:
3053:(9194): 1932–9.
3041:
3035:
3029:
3028:
3024:
3022:
3020:
3001:
2995:
2994:
2992:
2981:
2973:
2967:
2966:
2961:. Archived from
2951:
2945:
2944:
2934:
2910:
2904:
2903:
2901:
2899:
2884:
2878:
2877:
2867:
2835:
2829:
2828:
2800:
2794:
2793:
2765:
2759:
2758:
2727:J Cutan Med Surg
2722:
2716:
2715:
2687:
2681:
2680:
2678:
2676:
2637:Joint Bone Spine
2628:
2619:
2618:
2608:
2576:
2570:
2569:
2559:
2527:
2521:
2520:
2510:
2478:
2469:
2468:
2447:
2441:
2440:
2430:
2404:
2398:
2397:
2369:
2363:
2362:
2337:(9317): 1541–9.
2326:
2317:
2316:
2306:
2280:
2274:
2273:
2271:
2269:
2263:
2241:(18): 1398–405.
2230:
2221:
2215:
2214:
2178:
2172:
2171:
2169:
2150:
2144:
2143:
2115:
2109:
2108:
2106:
2104:
2085:
2070:
2069:
2067:
2065:
2043:
2034:
2033:
2031:
2029:
2011:"Inflectra EPAR"
2007:
1996:
1995:
1993:
1991:
1969:
1958:
1957:
1955:
1953:
1931:
1922:
1921:
1919:
1917:
1902:
1896:
1895:
1893:
1891:
1876:
1870:
1869:
1867:
1865:
1850:
1844:
1843:
1841:
1839:
1824:
1818:
1817:
1815:
1813:
1798:
1792:
1791:
1789:
1787:
1768:
1762:
1761:
1759:
1757:
1736:
1730:
1729:
1727:
1725:
1715:nctr-crs.fda.gov
1707:
1701:
1700:
1698:
1696:
1677:
1671:
1670:
1668:
1666:
1651:
1642:
1641:
1639:
1637:
1622:
1616:
1615:
1613:
1611:
1594:
1588:
1587:
1585:
1583:
1562:
1551:
1550:
1548:
1546:
1524:
1513:
1512:
1510:
1508:
1485:
1472:
1471:
1469:
1467:
1458:. 27 June 2016.
1444:
1433:
1432:
1430:
1428:
1405:
1392:
1391:
1389:
1387:
1364:
1111:variable regions
1052:thrombocytopenia
1010:6-mercaptopurine
998:reactivation of
992:reactivation of
960:
953:
949:
946:
940:
917:
909:
899:hemolytic anemia
895:Kawasaki Disease
863:plaque psoriasis
849:Behçet's disease
650:Behçet's disease
624:. This includes
607:
606:
599:
588:
586:
569:
563:
557:
551:
545:
525:
524:
510:
508:
493:
473:
453:
417:
397:
371:
325:
322:
317:
310:
307:
297:
294:
285:
282:
272:
269:
247:
200:
197:
179:
168:
165:
152:
138:
44:
37:
35:
21:
6803:
6802:
6798:
6797:
6796:
6794:
6793:
6792:
6758:Janssen Biotech
6733:
6732:
6731:
6721:
6719:
6711:
6709:
6704:
6703:
6688:Clinical trials
6663:
6618:
6602:
6531:
6452:
6443:Rozanolixizumab
6431:
6425:
6417:
6406:
6219:Lulizumab pegol
6097:
6029:
5963:
5683:
5674:
5644:
5639:
5585:Rozanolixizumab
5470:Deucravacitinib
5404:
5332:
5305:
5194:
4843:
4837:
4545:
4510:
4467:
4446:
4436:
4394:
4334:
4325:
4261:Antimetabolites
4252:
4246:
4232:
4202:
4197:
4142:
4122:
4063:Coppertone sign
4056:Schering-Plough
4051:
3940:
3931:Schering-Plough
3904:
3843:
3838:
3794:
3789:
3788:
3778:
3776:
3767:
3765:
3761:
3751:
3749:
3736:
3735:
3731:
3711:
3710:
3706:
3689:
3688:
3684:
3667:
3666:
3662:
3652:
3650:
3635:
3634:
3630:
3620:
3618:
3603:
3602:
3598:
3581:
3580:
3576:
3564:
3556:
3554:
3537:
3536:
3532:
3522:
3520:
3506:
3505:
3501:
3491:
3489:
3471:
3470:
3466:
3447:
3446:
3442:
3432:
3430:
3414:
3413:
3409:
3399:
3397:
3396:on 13 July 2011
3384:
3383:
3374:
3353:(16): 1443–53.
3344:
3343:
3339:
3316:10.1038/nri3834
3304:Nat Rev Immunol
3299:
3294:
3293:
3289:
3258:(13): 4025–31.
3245:
3244:
3240:
3196:
3195:
3191:
3186:
3182:
3177:
3173:
3141:
3140:
3136:
3090:
3089:
3082:
3043:
3042:
3038:
3026:
3018:
3016:
3003:
3002:
2998:
2990:
2979:
2975:
2974:
2970:
2965:on 4 July 2008.
2953:
2952:
2948:
2912:
2911:
2907:
2897:
2895:
2886:
2885:
2881:
2837:
2836:
2832:
2802:
2801:
2797:
2767:
2766:
2762:
2724:
2723:
2719:
2689:
2688:
2684:
2674:
2672:
2630:
2629:
2622:
2585:Ann. Rheum. Dis
2578:
2577:
2573:
2542:(3): CD003785.
2529:
2528:
2524:
2493:(4): CD005468.
2480:
2479:
2472:
2449:
2448:
2444:
2421:(23): 2462–76.
2406:
2405:
2401:
2371:
2370:
2366:
2328:
2327:
2320:
2282:
2281:
2277:
2267:
2265:
2261:
2228:
2223:
2222:
2218:
2180:
2179:
2175:
2152:
2151:
2147:
2117:
2116:
2112:
2102:
2100:
2087:
2086:
2073:
2063:
2061:
2045:
2044:
2037:
2027:
2025:
2009:
2008:
1999:
1989:
1987:
1971:
1970:
1961:
1951:
1949:
1935:"Remicade EPAR"
1933:
1932:
1925:
1915:
1913:
1904:
1903:
1899:
1889:
1887:
1878:
1877:
1873:
1863:
1861:
1852:
1851:
1847:
1837:
1835:
1826:
1825:
1821:
1811:
1809:
1800:
1799:
1795:
1785:
1783:
1770:
1769:
1765:
1755:
1753:
1738:
1737:
1733:
1723:
1721:
1709:
1708:
1704:
1694:
1692:
1687:. 2 July 2019.
1679:
1678:
1674:
1664:
1662:
1653:
1652:
1645:
1635:
1633:
1624:
1623:
1619:
1609:
1607:
1596:
1595:
1591:
1581:
1579:
1564:
1563:
1554:
1544:
1542:
1526:
1525:
1516:
1506:
1504:
1487:
1486:
1475:
1465:
1463:
1446:
1445:
1436:
1426:
1424:
1407:
1406:
1395:
1385:
1383:
1366:
1365:
1354:
1349:
1324:Crohn's disease
1316:
1259:
1253:
1241:Schering-Plough
1225:Janssen Biotech
1221:
1216:
1185:
1115:serum half-life
1088:
961:
950:
944:
941:
930:
918:
907:
905:Adverse effects
834:
801:
780:
760:
739:
723:Crohn's disease
715:
713:Crohn's disease
710:
626:Crohn's disease
602:
600:
597:(what is this?)
594:
584:
582:
572:
566:
560:
554:
548:
528:
504:
496:
476:
456:
436:
420:
400:
369:
345:Bioavailability
337:Pharmacokinetic
331:
315:
251:
215:
208:
189:
182:
28:
23:
22:
15:
12:
11:
5:
6801:
6799:
6791:
6790:
6785:
6783:TNF inhibitors
6780:
6775:
6770:
6765:
6760:
6755:
6750:
6745:
6735:
6734:
6730:
6729:
6706:
6705:
6702:
6701:
6700:
6699:
6696:
6685:
6679:
6673:
6672:
6669:
6668:
6665:
6664:
6662:
6661:
6656:
6651:
6646:
6640:
6638:
6631:
6624:
6623:
6620:
6619:
6617:
6616:
6610:
6608:
6604:
6603:
6601:
6600:
6595:
6590:
6585:
6580:
6575:
6570:
6565:
6560:
6555:
6550:
6545:
6539:
6537:
6533:
6532:
6530:
6529:
6524:
6519:
6514:
6509:
6504:
6499:
6494:
6489:
6484:
6479:
6473:
6471:
6464:
6458:
6457:
6454:
6453:
6451:
6450:
6445:
6440:
6434:
6432:
6427:
6426:
6408:
6407:
6401:
6396:
6391:
6386:
6381:
6376:
6371:
6366:
6361:
6356:
6351:
6346:
6341:
6336:
6331:
6326:
6321:
6316:
6311:
6306:
6301:
6296:
6291:
6286:
6281:
6276:
6271:
6266:
6261:
6256:
6251:
6246:
6243:+hyaluronidase
6236:
6231:
6226:
6221:
6216:
6211:
6206:
6201:
6196:
6191:
6186:
6181:
6176:
6171:
6166:
6161:
6156:
6151:
6146:
6141:
6136:
6131:
6126:
6121:
6116:
6107:
6105:
6099:
6098:
6096:
6095:
6090:
6085:
6080:
6075:
6070:
6065:
6060:
6055:
6050:
6045:
6039:
6037:
6031:
6030:
6028:
6027:
6022:
6017:
6012:
6007:
6002:
5997:
5992:
5987:
5982:
5977:
5971:
5969:
5965:
5964:
5962:
5961:
5951:
5950:
5945:
5940:
5930:
5929:
5924:
5919:
5914:
5909:
5899:
5898:
5893:
5888:
5883:
5878:
5873:
5868:
5863:
5858:
5853:
5847:
5842:
5837:
5832:
5827:
5822:
5817:
5812:
5807:
5802:
5797:
5792:
5787:
5782:
5777:
5772:
5767:
5762:
5757:
5752:
5747:
5742:
5737:
5732:
5727:
5722:
5717:
5712:
5700:
5698:
5691:
5685:
5684:
5675:
5673:
5672:
5665:
5658:
5650:
5641:
5640:
5638:
5637:
5632:
5627:
5622:
5617:
5612:
5607:
5602:
5597:
5592:
5587:
5582:
5577:
5572:
5567:
5562:
5557:
5552:
5547:
5542:
5537:
5532:
5527:
5522:
5517:
5512:
5507:
5502:
5497:
5494:+hyaluronidase
5487:
5482:
5477:
5475:Deuruxolitinib
5472:
5467:
5462:
5457:
5452:
5447:
5442:
5437:
5432:
5427:
5422:
5416:
5414:
5410:
5409:
5406:
5405:
5403:
5402:
5397:
5392:
5387:
5386:
5385:
5380:
5368:
5367:
5366:
5361:
5348:
5346:
5338:
5337:
5334:
5333:
5331:
5330:
5325:
5319:
5317:
5311:
5310:
5307:
5306:
5304:
5303:
5298:
5293:
5288:
5283:
5278:
5273:
5268:
5263:
5258:
5253:
5248:
5243:
5238:
5233:
5228:
5223:
5218:
5213:
5208:
5202:
5200:
5196:
5195:
5193:
5192:
5179:
5178:
5177:
5176:
5171:
5166:
5153:
5152:
5151:
5150:
5138:
5137:
5136:
5124:
5123:
5122:
5117:
5105:
5104:
5103:
5098:
5093:
5081:
5080:
5079:
5068:
5067:
5066:
5065:
5060:
5048:
5047:
5046:
5034:
5033:
5032:
5020:
5019:
5018:
5006:
5005:
5004:
4999:
4987:
4986:
4985:
4980:
4968:
4967:
4966:
4961:
4956:
4951:
4948:+hyaluronidase
4941:
4929:
4928:
4927:
4915:
4914:
4913:
4901:
4900:
4899:
4894:
4889:
4877:
4876:
4875:
4870:
4865:
4860:
4847:
4845:
4839:
4838:
4836:
4835:
4834:
4833:
4820:
4819:
4818:
4817:
4812:
4791:
4790:
4789:
4788:
4775:
4774:
4773:
4772:
4759:
4758:
4757:
4756:
4743:
4742:
4741:
4740:
4727:
4726:
4725:
4724:
4719:
4714:
4709:
4704:
4699:
4694:
4689:
4684:
4679:
4674:
4669:
4664:
4659:
4654:
4649:
4644:
4639:
4634:
4629:
4624:
4619:
4606:
4605:
4604:
4603:
4598:
4593:
4588:
4583:
4578:
4565:
4564:
4563:
4562:
4549:
4547:
4538:
4529:
4520:
4516:
4515:
4512:
4511:
4509:
4508:
4503:
4498:
4493:
4488:
4483:
4477:
4475:
4469:
4468:
4466:
4465:
4459:
4457:
4448:
4442:
4441:
4438:
4437:
4435:
4434:
4433:
4432:
4424:PDE4 inhibitor
4420:
4415:
4410:
4404:
4402:
4396:
4395:
4393:
4392:
4387:
4381:
4380:
4379:
4378:
4373:
4368:
4363:
4342:
4340:
4327:
4326:
4324:
4323:
4322:
4321:
4308:
4307:
4306:
4305:
4300:
4286:
4285:
4284:
4283:
4278:
4265:
4263:
4254:
4248:
4247:
4233:
4231:
4230:
4223:
4216:
4208:
4199:
4198:
4196:
4195:
4194:
4193:
4186:
4179:
4172:
4158:
4150:
4148:
4144:
4143:
4141:
4140:
4134:
4132:
4128:
4127:
4124:
4123:
4121:
4120:
4118:Urofollitropin
4115:
4110:
4105:
4100:
4095:
4090:
4085:
4080:
4075:
4070:
4065:
4059:
4057:
4050:
4049:
4044:
4039:
4034:
4029:
4024:
4019:
4014:
4009:
4004:
3999:
3994:
3989:
3984:
3979:
3974:
3969:
3964:
3959:
3954:
3948:
3946:
3942:
3941:
3939:
3938:
3933:
3928:
3923:
3918:
3912:
3910:
3906:
3905:
3903:
3902:
3897:
3892:
3887:
3882:
3877:
3872:
3870:William Kelley
3867:
3862:
3860:Johnnetta Cole
3857:
3851:
3849:
3845:
3844:
3839:
3837:
3836:
3829:
3822:
3814:
3808:
3807:
3793:
3792:External links
3790:
3787:
3786:
3759:
3729:
3704:
3682:
3660:
3628:
3596:
3574:
3530:
3499:
3464:
3440:
3407:
3372:
3337:
3287:
3238:
3189:
3180:
3171:
3152:(12): 907–16.
3134:
3103:(4): 219–227.
3080:
3036:
2996:
2968:
2946:
2905:
2879:
2830:
2795:
2776:(4): 751–767.
2760:
2717:
2682:
2620:
2571:
2522:
2470:
2459:(7): 1417–21.
2442:
2399:
2364:
2318:
2275:
2216:
2189:(3): 183–200.
2173:
2145:
2110:
2071:
2035:
1997:
1973:"Remsima EPAR"
1959:
1923:
1897:
1871:
1860:. 5 April 2024
1845:
1834:. 7 April 2023
1819:
1808:. 8 April 2022
1793:
1763:
1731:
1702:
1672:
1643:
1617:
1589:
1552:
1528:"Flixabi EPAR"
1514:
1473:
1434:
1393:
1351:
1350:
1348:
1345:
1315:
1312:
1252:
1249:
1245:Merck & Co
1239:in China, and
1220:
1217:
1215:
1212:
1193:George Kollias
1184:
1181:
1087:
1084:
1040:
1039:
1033:
1027:
1018:
1013:
1002:
996:
990:
969:TNF inhibiting
963:
962:
921:
919:
912:
906:
903:
833:
830:
800:
797:
779:
776:
759:
756:
738:
735:
714:
711:
709:
706:
609:
608:
591:
590:
580:
574:
573:
570:
564:
558:
552:
546:
541:
535:
534:
530:
529:
527:
526:
513:
511:
498:
497:
495:
494:
486:
484:
478:
477:
475:
474:
466:
464:
458:
457:
455:
454:
446:
444:
438:
437:
435:
434:
430:
428:
422:
421:
419:
418:
410:
408:
402:
401:
399:
398:
390:
388:
382:
381:
377:
376:
373:
364:
363:
357:
351:
350:
347:
341:
340:
333:
332:
330:
329:
320:
305:
292:
280:
266:
264:
258:
257:
253:
252:
250:
249:
236:
234:
228:
227:
218:
216:administration
210:
209:
207:
206:
204:
194:
192:
184:
183:
181:
180:
162:
160:
154:
153:
146:
140:
139:
132:
122:
121:
118:
112:
111:
108:
102:
101:
97:
96:
90:
84:
83:
69:
63:
62:
61:Whole antibody
59:
53:
52:
46:
45:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
6800:
6789:
6786:
6784:
6781:
6779:
6776:
6774:
6771:
6769:
6766:
6764:
6761:
6759:
6756:
6754:
6751:
6749:
6746:
6744:
6741:
6740:
6738:
6728:
6718:
6714:
6697:
6695:
6692:
6691:
6689:
6686:
6683:
6680:
6678:
6675:
6674:
6670:
6660:
6657:
6655:
6652:
6650:
6647:
6645:
6642:
6641:
6639:
6635:
6632:
6630:
6627:Inflammatory
6625:
6615:
6612:
6611:
6609:
6605:
6599:
6598:Tildrakizumab
6596:
6594:
6591:
6589:
6586:
6584:
6581:
6579:
6576:
6574:
6571:
6569:
6566:
6564:
6561:
6559:
6556:
6554:
6551:
6549:
6546:
6544:
6541:
6540:
6538:
6534:
6528:
6525:
6523:
6520:
6518:
6515:
6513:
6510:
6508:
6505:
6503:
6500:
6498:
6495:
6493:
6490:
6488:
6485:
6483:
6480:
6478:
6475:
6474:
6472:
6468:
6465:
6463:
6459:
6449:
6446:
6444:
6441:
6439:
6436:
6435:
6433:
6428:
6424:
6423:
6420:
6416:
6412:
6405:
6402:
6400:
6399:Vobarilizumab
6397:
6395:
6392:
6390:
6387:
6385:
6382:
6380:
6377:
6375:
6372:
6370:
6367:
6365:
6362:
6360:
6357:
6355:
6352:
6350:
6347:
6345:
6344:Spartalizumab
6342:
6340:
6337:
6335:
6332:
6330:
6327:
6325:
6322:
6320:
6317:
6315:
6312:
6310:
6307:
6305:
6302:
6300:
6297:
6295:
6292:
6290:
6287:
6285:
6282:
6280:
6277:
6275:
6272:
6270:
6269:Pembrolizumab
6267:
6265:
6262:
6260:
6257:
6255:
6252:
6250:
6247:
6244:
6240:
6237:
6235:
6232:
6230:
6229:Mogamulizumab
6227:
6225:
6222:
6220:
6217:
6215:
6212:
6210:
6207:
6205:
6202:
6200:
6197:
6195:
6192:
6190:
6187:
6185:
6182:
6180:
6177:
6175:
6172:
6170:
6167:
6165:
6162:
6160:
6157:
6155:
6152:
6150:
6149:Crizanlizumab
6147:
6145:
6142:
6140:
6137:
6135:
6132:
6130:
6127:
6125:
6122:
6120:
6117:
6115:
6112:
6109:
6108:
6106:
6104:
6100:
6094:
6091:
6089:
6086:
6084:
6081:
6079:
6076:
6074:
6071:
6069:
6066:
6064:
6061:
6059:
6056:
6054:
6051:
6049:
6046:
6044:
6043:Andecaliximab
6041:
6040:
6038:
6036:
6032:
6026:
6023:
6021:
6018:
6016:
6013:
6011:
6008:
6006:
6003:
6001:
5998:
5996:
5993:
5991:
5988:
5986:
5983:
5981:
5978:
5976:
5973:
5972:
5970:
5966:
5960:
5956:
5953:
5952:
5949:
5946:
5944:
5941:
5939:
5935:
5932:
5931:
5928:
5925:
5923:
5920:
5918:
5915:
5913:
5910:
5908:
5904:
5901:
5900:
5897:
5894:
5892:
5889:
5887:
5884:
5882:
5879:
5877:
5874:
5872:
5869:
5867:
5864:
5862:
5859:
5857:
5854:
5851:
5848:
5846:
5843:
5841:
5838:
5836:
5833:
5831:
5828:
5826:
5823:
5821:
5818:
5816:
5813:
5811:
5808:
5806:
5803:
5801:
5798:
5796:
5793:
5791:
5788:
5786:
5783:
5781:
5778:
5776:
5773:
5771:
5768:
5766:
5763:
5761:
5758:
5756:
5753:
5751:
5748:
5746:
5743:
5741:
5738:
5736:
5733:
5731:
5728:
5726:
5723:
5721:
5718:
5716:
5713:
5711:
5707:
5706:
5702:
5701:
5699:
5695:
5692:
5690:
5689:Immune system
5686:
5682:
5681:immune system
5678:
5671:
5666:
5664:
5659:
5657:
5652:
5651:
5648:
5636:
5633:
5631:
5628:
5626:
5625:Tildrakizumab
5623:
5621:
5618:
5616:
5613:
5611:
5608:
5606:
5603:
5601:
5598:
5596:
5593:
5591:
5588:
5586:
5583:
5581:
5578:
5576:
5573:
5571:
5568:
5566:
5563:
5561:
5558:
5556:
5555:Pegcetacoplan
5553:
5551:
5548:
5546:
5543:
5541:
5538:
5536:
5533:
5531:
5528:
5526:
5523:
5521:
5518:
5516:
5513:
5511:
5508:
5506:
5503:
5501:
5498:
5495:
5491:
5488:
5486:
5483:
5481:
5478:
5476:
5473:
5471:
5468:
5466:
5465:Darvadstrocel
5463:
5461:
5458:
5456:
5453:
5451:
5448:
5446:
5443:
5441:
5438:
5436:
5433:
5431:
5428:
5426:
5423:
5421:
5418:
5417:
5415:
5411:
5401:
5398:
5396:
5393:
5391:
5388:
5384:
5381:
5379:
5376:
5375:
5374:
5373:
5372:TNF inhibitor
5369:
5365:
5362:
5360:
5357:
5356:
5355:
5354:
5350:
5349:
5347:
5344:
5339:
5329:
5326:
5324:
5321:
5320:
5318:
5316:
5312:
5302:
5299:
5297:
5294:
5292:
5289:
5287:
5284:
5282:
5279:
5277:
5274:
5272:
5269:
5267:
5264:
5262:
5259:
5257:
5254:
5252:
5249:
5247:
5244:
5242:
5239:
5237:
5234:
5232:
5229:
5227:
5224:
5222:
5219:
5217:
5214:
5212:
5209:
5207:
5204:
5203:
5201:
5197:
5190:
5186:
5185:
5181:
5180:
5175:
5172:
5170:
5167:
5165:
5162:
5161:
5160:
5159:
5155:
5154:
5149:
5146:
5145:
5144:
5143:
5139:
5135:
5132:
5131:
5130:
5129:
5125:
5121:
5118:
5116:
5113:
5112:
5111:
5110:
5106:
5102:
5099:
5097:
5094:
5092:
5089:
5088:
5087:
5086:
5082:
5078:
5075:
5074:
5073:
5070:
5069:
5064:
5061:
5059:
5056:
5055:
5054:
5053:
5049:
5045:
5042:
5041:
5040:
5039:
5038:CD147/Basigin
5035:
5031:
5028:
5027:
5026:
5025:
5021:
5017:
5014:
5013:
5012:
5011:
5007:
5003:
5000:
4998:
4995:
4994:
4993:
4992:
4988:
4984:
4981:
4979:
4976:
4975:
4974:
4973:
4969:
4965:
4962:
4960:
4957:
4955:
4952:
4949:
4945:
4942:
4940:
4937:
4936:
4935:
4934:
4930:
4926:
4923:
4922:
4921:
4920:
4916:
4912:
4909:
4908:
4907:
4906:
4902:
4898:
4895:
4893:
4890:
4888:
4885:
4884:
4883:
4882:
4878:
4874:
4871:
4869:
4866:
4864:
4861:
4859:
4858:Muromonab-CD3
4856:
4855:
4854:
4853:
4849:
4848:
4846:
4840:
4832:
4829:
4828:
4827:
4826:
4822:
4821:
4816:
4813:
4811:
4808:
4807:
4806:
4805:
4801:
4797:
4793:
4792:
4787:
4784:
4783:
4782:
4781:
4777:
4776:
4771:
4768:
4767:
4766:
4765:
4761:
4760:
4755:
4752:
4751:
4750:
4749:
4745:
4744:
4739:
4736:
4735:
4734:
4733:
4732:Interleukin 5
4729:
4728:
4723:
4720:
4718:
4715:
4713:
4712:Tildrakizumab
4710:
4708:
4705:
4703:
4700:
4698:
4695:
4693:
4690:
4688:
4685:
4683:
4680:
4678:
4675:
4673:
4670:
4668:
4665:
4663:
4660:
4658:
4655:
4653:
4650:
4648:
4645:
4643:
4640:
4638:
4635:
4633:
4630:
4628:
4625:
4623:
4620:
4618:
4615:
4614:
4613:
4612:
4608:
4607:
4602:
4599:
4597:
4594:
4592:
4589:
4587:
4584:
4582:
4579:
4577:
4574:
4573:
4572:
4571:
4567:
4566:
4561:
4558:
4557:
4556:
4555:
4551:
4550:
4548:
4546:(noncellular)
4542:
4539:
4537:
4533:
4530:
4528:
4524:
4521:
4519:Extracellular
4517:
4507:
4504:
4502:
4499:
4497:
4494:
4492:
4489:
4487:
4486:Ridaforolimus
4484:
4482:
4479:
4478:
4476:
4474:
4470:
4464:
4461:
4460:
4458:
4456:
4452:
4449:
4445:Intracellular
4443:
4431:
4428:
4427:
4426:
4425:
4421:
4419:
4416:
4414:
4411:
4409:
4406:
4405:
4403:
4401:
4397:
4391:
4388:
4386:
4383:
4382:
4377:
4374:
4372:
4369:
4367:
4364:
4362:
4359:
4358:
4357:
4356:
4352:
4348:
4344:
4343:
4341:
4338:
4332:
4328:
4320:
4317:
4316:
4315:
4314:
4310:
4309:
4304:
4303:Teriflunomide
4301:
4299:
4296:
4295:
4293:
4292:
4288:
4287:
4282:
4279:
4277:
4274:
4273:
4272:
4271:
4267:
4266:
4264:
4262:
4258:
4255:
4251:Intracellular
4249:
4244:
4240:
4236:
4229:
4224:
4222:
4217:
4215:
4210:
4209:
4206:
4192:
4191:
4187:
4185:
4184:
4180:
4178:
4177:
4173:
4171:
4170:
4166:
4165:
4164:
4163:
4159:
4157:
4156:
4152:
4151:
4149:
4145:
4139:
4136:
4135:
4133:
4129:
4119:
4116:
4114:
4111:
4109:
4106:
4104:
4101:
4099:
4096:
4094:
4091:
4089:
4086:
4084:
4081:
4079:
4076:
4074:
4071:
4069:
4068:Desloratadine
4066:
4064:
4061:
4060:
4058:
4054:
4048:
4045:
4043:
4040:
4038:
4035:
4033:
4030:
4028:
4025:
4023:
4020:
4018:
4015:
4013:
4010:
4008:
4005:
4003:
4000:
3998:
3995:
3993:
3990:
3988:
3985:
3983:
3982:Fosaprepitant
3980:
3978:
3975:
3973:
3970:
3968:
3965:
3963:
3960:
3958:
3955:
3953:
3950:
3949:
3947:
3943:
3937:
3934:
3932:
3929:
3927:
3924:
3922:
3919:
3917:
3914:
3913:
3911:
3907:
3901:
3900:Peter Wendell
3898:
3896:
3895:Wendell Weeks
3893:
3891:
3888:
3886:
3883:
3881:
3878:
3876:
3873:
3871:
3868:
3866:
3863:
3861:
3858:
3856:
3855:Richard Clark
3853:
3852:
3850:
3846:
3842:
3835:
3830:
3828:
3823:
3821:
3816:
3815:
3812:
3805:
3800:
3796:
3795:
3791:
3774:
3770:
3763:
3760:
3747:
3743:
3739:
3733:
3730:
3725:
3721:
3719:
3714:
3708:
3705:
3700:
3696:
3692:
3686:
3683:
3678:
3674:
3670:
3664:
3661:
3648:
3644:
3643:
3642:Health Canada
3638:
3632:
3629:
3616:
3612:
3611:
3610:Health Canada
3606:
3600:
3597:
3592:
3588:
3584:
3578:
3575:
3571:
3570:public domain
3552:
3548:
3546:
3540:
3534:
3531:
3518:
3514:
3510:
3503:
3500:
3486:
3481:
3480:
3475:
3468:
3465:
3460:
3456:
3455:
3450:
3444:
3441:
3428:
3424:
3423:
3418:
3411:
3408:
3395:
3391:
3387:
3381:
3379:
3377:
3373:
3368:
3364:
3360:
3356:
3352:
3348:
3341:
3338:
3333:
3329:
3325:
3321:
3317:
3313:
3310:(6): 362–74.
3309:
3305:
3298:
3291:
3288:
3283:
3279:
3274:
3269:
3265:
3261:
3257:
3253:
3249:
3242:
3239:
3234:
3230:
3225:
3220:
3216:
3212:
3209:(6): 1483–9.
3208:
3204:
3200:
3193:
3190:
3184:
3181:
3175:
3172:
3167:
3163:
3159:
3155:
3151:
3147:
3146:
3138:
3135:
3130:
3126:
3121:
3116:
3111:
3106:
3102:
3098:
3094:
3087:
3085:
3081:
3076:
3072:
3068:
3064:
3060:
3056:
3052:
3048:
3040:
3037:
3033:
3032:public domain
3014:
3010:
3006:
3000:
2997:
2989:
2985:
2978:
2972:
2969:
2964:
2960:
2956:
2950:
2947:
2942:
2938:
2933:
2928:
2924:
2920:
2916:
2909:
2906:
2893:
2892:www.pcori.org
2889:
2883:
2880:
2875:
2871:
2866:
2861:
2857:
2853:
2849:
2845:
2841:
2834:
2831:
2826:
2822:
2818:
2814:
2811:(9): 926–34.
2810:
2806:
2799:
2796:
2791:
2787:
2783:
2779:
2775:
2771:
2764:
2761:
2756:
2752:
2748:
2744:
2740:
2736:
2732:
2728:
2721:
2718:
2713:
2709:
2705:
2701:
2697:
2693:
2686:
2683:
2670:
2666:
2662:
2658:
2654:
2650:
2646:
2643:(2): 118–24.
2642:
2638:
2634:
2627:
2625:
2621:
2616:
2612:
2607:
2602:
2598:
2594:
2590:
2586:
2582:
2575:
2572:
2567:
2563:
2558:
2553:
2549:
2545:
2541:
2537:
2533:
2526:
2523:
2518:
2514:
2509:
2504:
2500:
2496:
2492:
2488:
2484:
2477:
2475:
2471:
2466:
2462:
2458:
2454:
2446:
2443:
2438:
2434:
2429:
2424:
2420:
2416:
2415:
2410:
2403:
2400:
2395:
2391:
2387:
2383:
2379:
2375:
2368:
2365:
2360:
2356:
2352:
2348:
2344:
2340:
2336:
2332:
2325:
2323:
2319:
2314:
2310:
2305:
2300:
2297:(9): 876–85.
2296:
2292:
2291:
2286:
2279:
2276:
2260:
2256:
2252:
2248:
2244:
2240:
2236:
2235:
2227:
2220:
2217:
2212:
2208:
2204:
2200:
2196:
2192:
2188:
2184:
2177:
2174:
2168:
2163:
2159:
2155:
2149:
2146:
2141:
2137:
2133:
2129:
2125:
2121:
2114:
2111:
2098:
2094:
2090:
2084:
2082:
2080:
2078:
2076:
2072:
2059:
2055:
2053:
2048:
2047:"Zessly EPAR"
2042:
2040:
2036:
2023:
2019:
2017:
2012:
2006:
2004:
2002:
1998:
1985:
1981:
1979:
1974:
1968:
1966:
1964:
1960:
1947:
1943:
1941:
1936:
1930:
1928:
1924:
1911:
1907:
1901:
1898:
1885:
1881:
1875:
1872:
1859:
1855:
1849:
1846:
1833:
1829:
1823:
1820:
1807:
1803:
1797:
1794:
1781:
1777:
1773:
1767:
1764:
1751:
1747:
1746:
1745:Health Canada
1741:
1735:
1732:
1720:
1716:
1712:
1706:
1703:
1690:
1686:
1682:
1676:
1673:
1660:
1656:
1650:
1648:
1644:
1631:
1627:
1621:
1618:
1605:
1604:
1603:Health Canada
1599:
1593:
1590:
1577:
1573:
1572:
1571:Health Canada
1567:
1561:
1559:
1557:
1553:
1540:
1536:
1534:
1529:
1523:
1521:
1519:
1515:
1502:
1498:
1496:
1490:
1484:
1482:
1480:
1478:
1474:
1461:
1457:
1455:
1449:
1443:
1441:
1439:
1435:
1422:
1418:
1416:
1410:
1404:
1402:
1400:
1398:
1394:
1381:
1377:
1375:
1369:
1363:
1361:
1359:
1357:
1353:
1346:
1344:
1341:
1338:
1335:
1333:
1329:
1325:
1320:
1313:
1311:
1308:
1305:
1302:
1299:
1296:
1294:
1290:
1287:
1285:
1280:
1277:
1274:
1272:
1268:
1264:
1258:
1250:
1248:
1247:) elsewhere.
1246:
1243:(now part of
1242:
1238:
1234:
1230:
1226:
1218:
1213:
1211:
1209:
1205:
1202:(b. 1933) at
1201:
1196:
1194:
1190:
1182:
1180:
1178:
1174:
1170:
1166:
1162:
1158:
1153:
1151:
1147:
1143:
1139:
1138:transmembrane
1135:
1131:
1127:
1123:
1118:
1116:
1112:
1108:
1104:
1100:
1097:
1093:
1085:
1083:
1081:
1077:
1073:
1069:
1065:
1059:
1057:
1053:
1049:
1045:
1038:
1034:
1031:
1028:
1025:
1022:
1021:demyelinating
1019:
1017:
1014:
1011:
1007:
1003:
1001:
997:
995:
991:
989:
985:
984:
983:
981:
977:
973:
970:
959:
956:
948:
945:November 2009
938:
934:
928:
927:
922:This section
920:
916:
911:
910:
904:
902:
900:
896:
892:
887:
885:
880:
878:
873:
871:
866:
864:
859:
857:
852:
850:
845:
843:
839:
831:
829:
827:
823:
818:
814:
810:
806:
798:
796:
793:
789:
785:
777:
775:
773:
769:
764:
757:
755:
753:
748:
744:
736:
734:
732:
728:
724:
720:
707:
705:
703:
699:
694:
692:
686:
684:
680:
676:
672:
669:
666:
662:
657:
655:
651:
647:
643:
639:
635:
631:
627:
623:
619:
615:
605:
598:
592:
581:
579:
575:
542:
540:
536:
531:
523:
519:
518:DTXSID9040504
515:
514:
512:
503:
499:
492:
491:ChEMBL1201581
488:
487:
485:
483:
479:
472:
468:
467:
465:
463:
459:
452:
448:
447:
445:
443:
439:
432:
431:
429:
427:
423:
416:
412:
411:
409:
407:
403:
396:
392:
391:
389:
387:
383:
378:
374:
372:
365:
361:
358:
356:
352:
348:
346:
342:
338:
334:
328: Rx-only
321:
318:
306:
303:
293:
290:
281:
278:
268:
267:
265:
263:
259:
254:
246:
241:
238:
237:
235:
233:
229:
226:
222:
219:
217:
211:
205:
196:
195:
193:
191:
185:
178:
173:
164:
163:
161:
159:
155:
151:
147:
145:
141:
137:
133:
131:
127:
123:
119:
117:
113:
109:
107:
103:
100:Clinical data
98:
94:
91:
89:
85:
81:
77:
73:
70:
68:
64:
60:
58:
54:
51:
47:
43:
38:
30:
19:
6588:Risankizumab
6573:Lebrikizumab
6553:Clazakizumab
6543:Anrukinzumab
6522:Tralokinumab
6438:Otelixizumab
6418:
6410:
6409:
6379:Tregalizumab
6364:Tislelizumab
6334:Satralizumab
6314:Rontalizumab
6309:Retifanlimab
6284:Plozalizumab
6264:Pateclizumab
6259:Pascolizumab
6254:Ozoralizumab
6204:Lampalizumab
6194:Inebilizumab
6184:Fontolizumab
6134:Camrelizumab
6129:Benralizumab
6124:Atezolizumab
6110:
6067:
6053:Clenoliximab
5954:
5938:Bertilimumab
5933:
5922:Tremelimumab
5902:
5825:Mavrilimumab
5815:Lirentelimab
5810:Lerdelimumab
5785:Fresolimumab
5725:Atorolimumab
5703:
5635:Upadacitinib
5595:Satralizumab
5580:Ritlecitinib
5575:Risankizumab
5370:
5351:
5291:Teprotumumab
5241:Inebilizumab
5236:Fontolizumab
5216:Atorolimumab
5184:T-lymphocyte
5182:
5156:
5140:
5126:
5107:
5096:Lerdelimumab
5091:Bertilimumab
5083:
5071:
5050:
5036:
5022:
5008:
4989:
4970:
4954:Pascolizumab
4939:Obinutuzumab
4931:
4917:
4903:
4887:Clenoliximab
4879:
4863:Otelixizumab
4850:
4823:
4810:Lebrikizumab
4794:
4778:
4762:
4746:
4730:
4687:Satralizumab
4677:Risankizumab
4609:
4595:
4568:
4552:
4544:Serum target
4496:Temsirolimus
4422:
4413:Pomalidomide
4408:Lenalidomide
4366:Pimecrolimus
4345:
4319:Methotrexate
4311:
4289:
4276:Azathioprine
4268:
4253:(initiation)
4189:
4182:
4175:
4168:
4160:
4153:
4147:Publications
4108:Temozolomide
4087:
4007:Omarigliptin
3909:Subsidiaries
3890:Samuel Thier
3885:Anne Tatlock
3880:Thomas Shenk
3777:. Retrieved
3762:
3750:. Retrieved
3746:the original
3741:
3732:
3716:
3707:
3694:
3685:
3672:
3663:
3651:. Retrieved
3640:
3631:
3619:. Retrieved
3608:
3599:
3586:
3577:
3555:. Retrieved
3542:
3533:
3521:. Retrieved
3512:
3507:Serebrov M.
3502:
3490:. Retrieved
3485:the original
3477:
3467:
3459:the original
3452:
3443:
3431:. Retrieved
3420:
3410:
3398:. Retrieved
3394:the original
3350:
3347:Mol. Immunol
3346:
3340:
3307:
3303:
3290:
3255:
3251:
3241:
3206:
3202:
3192:
3183:
3174:
3149:
3143:
3137:
3100:
3096:
3050:
3046:
3039:
3017:. Retrieved
3013:the original
2999:
2988:the original
2971:
2963:the original
2958:
2949:
2922:
2919:N Engl J Med
2918:
2908:
2896:. Retrieved
2894:. 9 May 2024
2891:
2882:
2847:
2843:
2833:
2808:
2804:
2798:
2773:
2769:
2763:
2733:(2): 77–89.
2730:
2726:
2720:
2698:(5): 712–9.
2695:
2691:
2685:
2673:. Retrieved
2640:
2636:
2588:
2584:
2574:
2539:
2535:
2525:
2490:
2486:
2456:
2453:J. Rheumatol
2452:
2445:
2418:
2412:
2402:
2380:(1): 131–7.
2377:
2373:
2367:
2334:
2330:
2294:
2288:
2278:
2266:. Retrieved
2238:
2232:
2219:
2186:
2182:
2176:
2167:10665/345533
2157:
2148:
2123:
2119:
2113:
2101:. Retrieved
2092:
2062:. Retrieved
2050:
2026:. Retrieved
2014:
1988:. Retrieved
1976:
1950:. Retrieved
1938:
1914:. Retrieved
1912:. 2 May 2024
1909:
1900:
1888:. Retrieved
1883:
1874:
1862:. Retrieved
1857:
1848:
1836:. Retrieved
1831:
1822:
1810:. Retrieved
1805:
1796:
1784:. Retrieved
1775:
1766:
1754:. Retrieved
1743:
1734:
1722:. Retrieved
1714:
1705:
1693:. Retrieved
1684:
1675:
1663:. Retrieved
1634:. Retrieved
1629:
1620:
1608:. Retrieved
1606:. 8 May 2018
1601:
1592:
1580:. Retrieved
1569:
1543:. Retrieved
1531:
1505:. Retrieved
1492:
1464:. Retrieved
1451:
1425:. Retrieved
1412:
1384:. Retrieved
1371:
1342:
1339:
1336:
1321:
1317:
1309:
1306:
1303:
1300:
1297:
1291:
1288:
1281:
1278:
1275:
1260:
1237:Xian Janssen
1222:
1197:
1186:
1173:TNF-receptor
1154:
1119:
1094:human-mouse
1089:
1086:Pharmacology
1068:azathioprine
1064:methotrexate
1060:
1056:pancytopenia
1041:
1000:tuberculosis
966:
951:
942:
931:Please help
926:verification
923:
888:
881:
874:
867:
860:
853:
846:
835:
809:cyclosporine
802:
781:
765:
761:
740:
731:inflammation
716:
708:Medical uses
695:
687:
658:
617:
613:
612:
601:
595:
368:Elimination
262:Legal status
256:Legal status
225:subcutaneous
158:License data
29:
6684:from market
6654:Lemalesomab
6649:Fanolesomab
6644:Besilesomab
6583:Perakizumab
6568:Mirikizumab
6558:Gevokizumab
6548:Bimekizumab
6527:Ustekinumab
6512:Secukinumab
6497:Fezakinumab
6492:Canakinumab
6487:Briakinumab
6462:Interleukin
6415:Dostarlimab
6394:Visilizumab
6389:Vedolizumab
6384:Vatelizumab
6374:Toralizumab
6369:Tocilizumab
6354:Teclistamab
6329:Samalizumab
6319:Rovelizumab
6299:Ravulizumab
6279:Pidilizumab
6274:Pexelizumab
6239:Ocrelizumab
6234:Natalizumab
6224:Mepolizumab
6214:Ligelizumab
6209:Letolizumab
6179:Etrolizumab
6169:Epratuzumab
6139:Cedelizumab
6093:Vapaliximab
6088:Teneliximab
6078:Lumiliximab
6063:Gomiliximab
6048:Basiliximab
6020:Vepalimomab
6005:Nerelimomab
5990:Gavilimomab
5985:Faralimomab
5980:Elsilimomab
5955:Combination
5948:Zanolimumab
5943:Ontamalimab
5891:Ulocuplumab
5886:Tezepelumab
5876:Sifalimumab
5856:Pamrevlumab
5835:Morolimumab
5830:Metelimumab
5800:Lanadelumab
5735:Avdoralimab
5720:Anifrolumab
5630:Tofacitinib
5570:Ravulizumab
5560:Pirfenidone
5550:Peficitinib
5450:Canakinumab
5440:Briakinumab
5430:Bimekizumab
5425:Baricitinib
5390:Aflibercept
5301:Vepalimomab
5296:Vapaliximab
5271:Rovelizumab
5261:Pexelizumab
5251:Morolimumab
5226:Cedelizumab
5211:Anifrolumab
5206:Alemtuzumab
5164:Basiliximab
5134:Tocilizumab
5120:Vedolizumab
5115:Natalizumab
5101:Metelimumab
5044:Gavilimomab
5002:Toralizumab
4997:Teneliximab
4983:Lumiliximab
4978:Gomiliximab
4964:Ublituximab
4944:Ocrelizumab
4897:Zanolimumab
4873:Visilizumab
4831:Secukinumab
4815:Ustekinumab
4786:Elsilimomab
4770:Faralimomab
4738:Mepolizumab
4722:Ustekinumab
4717:Tocilizumab
4692:Secukinumab
4642:Canakinumab
4632:Briakinumab
4627:Bimekizumab
4622:Basiliximab
4611:Interleukin
4601:Nerelimomab
4506:Zotarolimus
4447:(reception)
4418:Thalidomide
4376:Voclosporin
4361:Ciclosporin
4355:Calcineurin
4351:Cyclophilin
4298:Leflunomide
4294:inhibitors
4083:Famciclovir
4037:Sitagliptin
4032:Simvastatin
4017:Rizatriptan
4012:Raltegravir
4002:Montelukast
3977:Finasteride
3952:Alendronate
3779:1 September
3400:14 November
3203:J. Exp. Med
3019:15 November
1665:25 December
1598:"Arthritis"
1257:Biosimilars
1251:Biosimilars
1048:neutropenia
994:hepatitis B
870:sarcoidosis
698:biosimilars
589: g·mol
395:170277-31-3
380:Identifiers
221:Intravenous
144:MedlinePlus
116:Biosimilars
106:Trade names
6737:Categories
6614:Lokivetmab
6607:Veterinary
6593:Spesolimab
6578:Olokizumab
6563:Ixekizumab
6507:Guselkumab
6502:Fletikumab
6482:Brazikumab
6477:Bermekimab
6448:Sutimlimab
6422:Ibalizumab
6359:Teplizumab
6339:Siplizumab
6324:Ruplizumab
6304:Reslizumab
6294:Quilizumab
6249:Omalizumab
6199:Itolizumab
6189:Frexalimab
6164:Efalizumab
6159:Eculizumab
6154:Daclizumab
6119:Aselizumab
6114:Apolizumab
6083:Priliximab
6068:Infliximab
6010:Odulimomab
6000:Maslimomab
5995:Inolimomab
5975:Afelimomab
5912:Durvalumab
5907:Ipilimumab
5896:Varlilumab
5866:Relatlimab
5861:Placulumab
5805:Lenzilumab
5780:Emapalumab
5765:Cemiplimab
5750:Brodalumab
5745:Bleselumab
5715:Adalimumab
5620:Sutimlimab
5615:Spesolimab
5600:Siltuximab
5540:Olokizumab
5530:Ixekizumab
5525:Itacitinib
5515:Guselkumab
5510:Fingolimod
5505:Filgotinib
5455:Crovalimab
5445:Brodalumab
5435:Blisibimod
5400:Rilonacept
5383:Opinercept
5378:Etanercept
5364:Belatacept
5315:Polyclonal
5276:Siplizumab
5266:Reslizumab
5256:Ofatumumab
5246:Maslimomab
5231:Emapalumab
5174:Inolimomab
5169:Daclizumab
5148:Odulimomab
5063:Ruplizumab
5058:Frexalimab
5016:Aselizumab
4911:Efalizumab
4868:Teplizumab
4764:Interferon
4754:Omalizumab
4707:Spesolimab
4697:Siltuximab
4672:Rilonacept
4667:Olokizumab
4657:Ixekizumab
4652:Guselkumab
4647:Daclizumab
4637:Brodalumab
4596:Infliximab
4581:Afelimomab
4576:Adalimumab
4560:Eculizumab
4536:Monoclonal
4527:Antibodies
4501:Umirolimus
4481:Everolimus
4430:Apremilast
4390:Gusperimus
4371:Tacrolimus
4339:inhibitors
4331:Macrolides
4313:antifolate
4190:Geriatrics
4183:Veterinary
4131:Facilities
4098:Mometasone
4093:Loratadine
4088:Infliximab
4047:Vorinostat
4042:Vericiguat
3997:Lovastatin
3957:Aprepitant
3936:Viralytics
3804:Infliximab
3673:rxlist.com
3587:nasdaq.com
3557:6 December
3523:26 October
2675:4 November
1724:22 October
1347:References
1263:biosimilar
1255:See also:
1235:in Japan,
1200:Jan VilÄŤek
1169:Etanercept
1161:adalimumab
1146:adalimumab
1134:adalimumab
1044:leukopenia
1035:new-onset
988:infections
826:dactylitis
822:enthesitis
817:adalimumab
813:etanercept
719:phenotypes
614:Infliximab
578:Molar mass
451:B72HH48FLU
426:ChemSpider
386:CAS Number
355:Metabolism
177:Infliximab
34:Infliximab
6694:Phase III
6682:Withdrawn
6659:Sulesomab
6536:Humanized
6517:Sirukumab
6349:Talizumab
6174:Erlizumab
6103:Humanized
6073:Keliximab
6058:Galiximab
5917:Nivolumab
5881:Tabalumab
5871:Sarilumab
5845:Oleclumab
5840:Namilumab
5820:Lirilumab
5795:Ianalumab
5790:Golimumab
5775:Eldelumab
5770:Dupilumab
5740:Belimumab
5710:Abrilumab
5610:Sirukumab
5605:Siponimod
5590:Sarilumab
5565:Ponesimod
5535:Netakimab
5520:Iptacopan
5500:Etrasimod
5460:Danicopan
5395:Alefacept
5359:Abatacept
5281:Talizumab
5221:Begelomab
5077:Belimumab
5030:Galiximab
4959:Rituximab
4925:Erlizumab
4892:Keliximab
4702:Sirukumab
4682:Sarilumab
4662:Netakimab
4591:Golimumab
4491:Sirolimus
4073:Ezetimibe
4022:Rofecoxib
3987:Indinavir
3967:Ezetimibe
3962:Ertapenem
3752:20 August
2665:205754989
2093:Drugs.com
1695:13 August
1685:Drugs.com
1219:Marketing
1157:golimumab
1072:psoriasis
1042:Cases of
1030:psoriasis
1026:disorders
772:remission
679:receptors
642:psoriasis
370:half-life
214:Routes of
188:Pregnancy
136:Monograph
130:Drugs.com
6727:Medicine
6035:Chimeric
5927:Urelumab
5850:Oxelumab
5760:Carlumab
5730:Avelumab
5679:for the
5545:Ozanimod
5420:Avacopan
5413:Unsorted
5199:Unsorted
5109:Integrin
4842:Cellular
4617:Anakinra
4463:Anakinra
4385:Abetimus
4237: /
4113:Tibolone
3992:Losartan
3945:Products
3773:Archived
3724:Archived
3699:Archived
3677:Archived
3647:Archived
3615:Archived
3591:Archived
3551:Archived
3517:Archived
3513:BioWorld
3427:Archived
3324:26008591
3166:11259725
3129:26600980
3067:10622295
3045:Group".
2959:Remicade
2941:11596589
2874:29442540
2825:17290043
2790:26593147
2755:23838714
2747:15685387
2712:22071463
2669:Archived
2657:24556284
2615:12379622
2566:12137712
2517:25887212
2508:11200207
2465:16724373
2437:16339095
2394:12617888
2351:12047962
2313:14985485
2259:Archived
2255:10228190
2211:21302609
2203:12744819
2156:(2021).
2140:10440618
2097:Archived
2058:Archived
2022:Archived
1984:Archived
1946:Archived
1910:DailyMed
1884:DailyMed
1858:DailyMed
1832:DailyMed
1806:DailyMed
1780:Archived
1756:25 March
1750:Archived
1689:Archived
1659:Archived
1636:13 April
1610:13 April
1576:Archived
1539:Archived
1501:Archived
1460:Archived
1421:Archived
1380:Archived
1229:Centocor
1208:Centocor
1142:receptor
1126:affinity
1092:chimeric
1037:vitiligo
986:serious
828:in PsA.
727:fistulae
683:cytokine
671:biologic
665:chimeric
618:Remicade
604:(verify)
406:DrugBank
375:9.5 days
232:ATC code
190:category
172:DailyMed
110:Remicade
72:Chimeric
18:Remicade
6629:lesions
6404:TGN1412
6289:PRO 140
5341:-cept (
3492:1 March
3433:27 June
3367:8232330
3332:1550839
3282:1721867
3233:1660525
3224:2119031
3120:4644886
3007:. U.S.
2982:. U.S.
2898:30 June
2865:6481621
2606:1766720
2557:8729322
2359:1905194
2103:15 July
2064:2 April
2028:1 March
1990:1 March
1952:2 April
1786:2 April
1582:7 April
1545:2 April
1507:8 April
1466:8 April
1427:8 April
1386:8 April
1282:The US
1267:Hospira
1183:History
1175:and an
1140:-, and
1130:T cells
1004:lethal
768:steroid
752:placebo
539:Formula
415:DB00065
319:Rx-only
316:WARNING
287::
248:)
242: (
240:L04AB02
203: C
174::
150:a604023
6713:Portal
6677:WHO-EM
6419:Other:
5353:CTLA-4
5343:Fusion
4844:target
4825:IL-17A
4802:, and
4335:other
4176:Manual
3720:(NICE)
3653:29 May
3621:29 May
3365:
3330:
3322:
3280:
3273:453150
3270:
3231:
3221:
3164:
3127:
3117:
3075:104011
3073:
3065:
3047:Lancet
2939:
2872:
2862:
2823:
2788:
2753:
2745:
2710:
2663:
2655:
2613:
2603:
2564:
2554:
2515:
2505:
2463:
2435:
2392:
2357:
2349:
2331:Lancet
2311:
2268:5 July
2253:
2209:
2201:
2138:
1916:22 May
1890:22 May
1864:22 May
1838:22 May
1812:22 May
1293:Biogen
1163:, and
1150:lysing
1109:chain
1078:, and
1054:, and
980:Humira
976:Enbrel
815:, and
717:Three
648:, and
482:ChEMBL
471:D02598
362:system
313:
300:
289:â„ž-only
275:
170:
88:Target
67:Source
6637:Mouse
6470:Human
5968:Mouse
5934:Other
5697:Human
5142:LFA-1
5052:CD154
4905:CD11a
4804:IL-23
4800:IL-13
4796:IL-12
4400:IMiDs
4169:Index
3547:(FDA)
3543:U.S.
3328:S2CID
3300:(PDF)
3071:S2CID
2991:(PDF)
2980:(PDF)
2751:S2CID
2661:S2CID
2355:S2CID
2262:(PDF)
2229:(PDF)
2207:S2CID
2054:(EMA)
2018:(EMA)
1980:(EMA)
1942:(EMA)
1535:(EMA)
1497:(FDA)
1493:U.S.
1456:(FDA)
1452:U.S.
1417:(FDA)
1413:U.S.
1376:(FDA)
1372:U.S.
1122:TNF-α
1107:light
1103:heavy
1070:) in
832:Other
747:bowel
675:TNF-α
95:(TNF)
80:human
76:mouse
5072:BLyS
5024:CD80
4991:CD40
4972:CD23
4933:CD20
4919:CD18
4780:IL-6
4473:mTOR
4347:FKBP
4337:IL-2
3781:2017
3754:2011
3655:2022
3623:2022
3559:2019
3525:2014
3494:2020
3435:2013
3402:2009
3363:PMID
3320:PMID
3278:PMID
3229:PMID
3162:PMID
3125:PMID
3063:PMID
3021:2009
2937:PMID
2900:2024
2870:PMID
2821:PMID
2786:PMID
2743:PMID
2708:PMID
2677:2018
2653:PMID
2611:PMID
2562:PMID
2540:2002
2513:PMID
2491:2015
2461:PMID
2433:PMID
2390:PMID
2347:PMID
2309:PMID
2270:2019
2251:PMID
2199:PMID
2136:PMID
2105:2019
2066:2020
2030:2020
1992:2020
1954:2020
1918:2024
1892:2024
1866:2024
1840:2024
1814:2024
1788:2024
1758:2024
1726:2023
1697:2020
1667:2023
1638:2024
1612:2024
1584:2024
1547:2020
1509:2024
1468:2024
1429:2024
1388:2024
1328:CDAI
1105:and
893:for
891:IVIG
745:and
743:skin
565:1987
559:1694
553:9912
547:6428
462:KEGG
442:UNII
433:none
339:data
126:AHFS
57:Type
5085:CAT
4881:CD4
4852:CD3
4570:TNF
4243:L04
3355:doi
3312:doi
3268:PMC
3260:doi
3219:PMC
3211:doi
3207:174
3154:doi
3150:344
3115:PMC
3105:doi
3055:doi
3051:354
2927:doi
2923:345
2860:PMC
2852:doi
2813:doi
2809:175
2778:doi
2735:doi
2700:doi
2645:doi
2601:PMC
2593:doi
2552:PMC
2544:doi
2503:PMC
2495:doi
2423:doi
2419:353
2382:doi
2339:doi
2335:359
2299:doi
2295:350
2243:doi
2239:340
2191:doi
2162:hdl
2128:doi
1719:FDA
1179:).
1096:IgG
935:by
803:In
792:Th2
788:Th1
784:TNF
733:).
587:.64
585:190
583:144
507:EPA
302:POM
245:WHO
6739::
6690::
6413::
5957::
5936::
5905::
5708::
4798:,
3771:.
3740:.
3715:.
3693:.
3675:.
3671:.
3639:.
3607:.
3585:.
3541:.
3515:.
3511:.
3476:.
3451:.
3425:.
3419:.
3375:^
3361:.
3351:30
3349:.
3326:.
3318:.
3308:15
3306:.
3302:.
3276:.
3266:.
3256:10
3254:.
3250:.
3227:.
3217:.
3205:.
3201:.
3160:.
3148:.
3123:.
3113:.
3099:.
3095:.
3083:^
3069:.
3061:.
3049:.
2957:.
2935:.
2921:.
2917:.
2890:.
2868:.
2858:.
2848:36
2846:.
2842:.
2819:.
2807:.
2784:.
2774:36
2772:.
2749:.
2741:.
2729:.
2706:.
2696:41
2694:.
2667:.
2659:.
2651:.
2641:81
2639:.
2635:.
2623:^
2609:.
2599:.
2589:61
2587:.
2583:.
2560:.
2550:.
2538:.
2534:.
2511:.
2501:.
2489:.
2485:.
2473:^
2457:33
2455:.
2431:.
2417:.
2411:.
2388:.
2378:17
2376:.
2353:.
2345:.
2333:.
2321:^
2307:.
2293:.
2287:.
2257:.
2249:.
2237:.
2231:.
2205:.
2197:.
2185:.
2134:.
2124:21
2122:.
2091:.
2074:^
2056:.
2049:.
2038:^
2020:.
2013:.
2000:^
1982:.
1975:.
1962:^
1944:.
1937:.
1926:^
1908:.
1882:.
1856:.
1830:.
1804:.
1774:.
1742:.
1717:.
1713:.
1683:.
1646:^
1628:.
1600:.
1568:.
1555:^
1537:.
1530:.
1517:^
1491:.
1476:^
1450:.
1437:^
1411:.
1396:^
1370:.
1355:^
1167:.
1159:,
1082:.
1074:,
1050:,
1046:,
901:.
851:.
844:.
704:.
644:,
640:,
636:,
632:,
628:,
571:46
324:EU
309:US
296:UK
284:CA
277:S4
271:AU
223:,
199:AU
167:US
6715::
6245:)
6241:(
5852:§
5669:e
5662:t
5655:v
5496:)
5492:(
5345:)
5191:)
5187:(
4950:)
4946:(
4353:/
4349:/
4333:/
4245:)
4241:(
4227:e
4220:t
4213:v
3833:e
3826:t
3819:v
3783:.
3756:.
3657:.
3625:.
3572:.
3561:.
3527:.
3496:.
3437:.
3404:.
3369:.
3357::
3334:.
3314::
3284:.
3262::
3235:.
3213::
3168:.
3156::
3131:.
3107::
3101:6
3077:.
3057::
3034:.
3023:.
2943:.
2929::
2902:.
2876:.
2854::
2827:.
2815::
2792:.
2780::
2757:.
2737::
2731:8
2714:.
2702::
2679:.
2647::
2617:.
2595::
2568:.
2546::
2519:.
2497::
2467:.
2439:.
2425::
2396:.
2384::
2361:.
2341::
2315:.
2301::
2272:.
2245::
2213:.
2193::
2187:6
2164::
2142:.
2130::
2107:.
2068:.
2032:.
1994:.
1956:.
1920:.
1894:.
1868:.
1842:.
1816:.
1790:.
1760:.
1728:.
1699:.
1640:.
1614:.
1586:.
1549:.
1511:.
1470:.
1431:.
1390:.
1012:)
958:)
952:(
947:)
943:(
929:.
568:S
562:O
556:N
550:H
544:C
509:)
505:(
326::
311::
298::
273::
201::
128:/
82:)
78:/
74:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
